Leukemia Therapeutics Market Research Report: by Type (Chemotherapy, Biological, Targeted, Radiation), by Application (Acute Lymphocytic Leukemia, Acute Myelogenous Leukemia, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia) - Forecast Till 2027
ID: MRFR/HC/5956-HCR | February 2021 | Region: Global | 110 pages
Leukemia Therapeutics Market Scenario
Leukemia therapeutics market is expected to grow significantly over the forecast period. It is anticipated that the market held value of USD 10.7 billion in 2017 and is projected to grow at a CAGR of 5.3% over the forecast period.
Leukemia is blood cancer which most commonly in adults and children. Acute lymphocytic leukemia, acute myelogenous leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia are the major types of the leukemia. leukemia therapeutics are used in treating the leukemia.
The factors such as innovative therapies to drive the market for leukemia, increase prevalence of leukemia, and increasing older population are expected to propel the growth of the market. However, high cost required for the development of new therapeutics hamper the leukemia therapeutics market growth over the forecast period.
Leukemia Therapeutics Market Segmentation
The global leukemia therapeutics market has been segmented into type, applications, and region.
Based on type, market is segmented into chemotherapy, biological therapy, targeted therapy, radiation therapy, and stem cell transplant. The chemotherapy segment is expected to account for the largest share segment of the market in 2017. Chemotherapy segment further sub segmented into alkylating agents, antimetabolites, antitumor antibiotics, and others.
Based on applications, market is segmented into acute lymphocytic leukemia, acute myelogenous leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, and others.
The market segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The market in the Americas further segmented into North America and Latin America, with the North American market divided into the US and Canada.
The European market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The leukemia therapeutics market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The market in the Middle East & Africa segmented into the Middle East and Africa.
Regional Market Summary
Geographically, the Americas is anticipated to dominate the global leukemia therapeutics market owing to a well-established player, innovative therapies to drive the market for leukemia, increase prevalence of leukemia, and increasing older population.
Europe is expected to hold the second largest position in the global market. The market growth in this region is attributed to increase prevalence of leukemia.
The market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. The Asia-Pacific region is expected to be fastest growing region.
The Middle East & Africa has the least share of the leukemia therapeutics market.
Market of Leukemia Therapeutics, by Treatment Type
- Chemotherapy
- Alkylating Agents
- Antimetabolites
- Antitumor Antibiotics
- Others
- Biological Therapy
- Targeted Therapy
- Radiation Therapy
- Stem Cell Transplant
- Others
Market of Leukemia Therapeutics, by Application
- Acute Lymphocytic Leukemia
- Acute Myelogenous Leukemia
- Chronic Lymphocytic Leukemia
- Chronic Myelogenous Leukemia
- Others
Market of Leukemia Therapeutics, by Region
- Americas
- North America
- US
- Canada
- Latin America
- Europe
- Western Europe
- Germany
- France
- Italy
- Spain
- UK
- Rest of Western Europe
- Eastern Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- The Middle East & Africa
- Middle East
- Africa
Market of Leukemia Therapeutics, by Key Players
- Eisai Co., Ltd (Japan)
- Novartis AG (Switzerland)
- Pfizer Inc. (US)
- GlaxoSmithKline plc (UK)
- Bristol-Myers Squibb Company (US)
- Hoffmann-La Roche AG (Switzerland)
- Sanofi S.A. (France)
- Teva Pharmaceutical Industries Ltd (Israel)
- Amgen Inc (US)
- Takeda Pharmaceutical Company Ltd (Japan)
Intended Audience
- Leukemia Therapeutics Manufacturers and Vendors
- Research Organization
- Various Research and Consulting Firms
- Cancer Organization and Association
Report Scope:
| Report Attribute/Metric | Details |
|---|---|
| Market Size | 2017 : USD 10.7 Billion |
| CAGR | 5.3% (2018 - 2023) |
| Base Year | 2019 |
| Forecast Period | 2020-2027 |
| Historical Data | 2018 |
| Forecast Units | Value (USD Million) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | By Type, Application, Regions |
| Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
| Key Vendors | Eisai Co., Ltd (Japan), Novartis AG (Switzerland), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Bristol-Myers Squibb Company (US), F. Hoffmann-La Roche AG (Switzerland), Sanofi S.A. (France), Teva Pharmaceutical Industries Ltd (Israel), Amgen Inc (US), and Takeda Pharmaceutical Company Ltd (Japan). |
| Key Market Opportunities | Joint ventures, strategic alliances, mergers and acquisitions and new product developments |
| Key Market Drivers |
|
Frequently Asked Questions (FAQ) :
The market is projected to grow at a 5.3% CAGR between 2018-2023.
The Americas is expected to dominate the market.
The acute lymphocytic leukemia segment will dominate the market.
Increasing prevalence of leukemia, increasing older population, and availability of innovative therapies are boosting market growth.
High cost may restrict the growth of the market.
This table of content is tentative and subject to change as the research progresses.
Please Note: Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.